NCT05443984 - JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

January 17, 2022

Primary Completion Date

January 5, 2023

Study Completion Date

January 5, 2023

Conditions

Erosive Esophagitis

Interventions

DRUG

JP-1366 20mg

1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)

DRUG

Esomeprazole 40mg

1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)

Trial Locations (1)

Asan Medical Center and 26 hospitals, Seoul